Search - tctmd.com

Displaying 581 - 600 of 725

Sort: Relevancy | Date

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

News Industry News

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

May 15, 2015

News Industry News

Knowledge Gaps and Misperceptions on Impact of Atrial Fibrillation and Stroke Exist Among Patients, Caregivers and Physicians

May 13, 2015

News Daily News

Post-TAVR Thrombus May Be More Common Than Thought, Often Subclinical

L.A. McKeown

May 06, 2015

News Daily News

Silent A-fib After Acute MI Portends Poor Outcome

Yael L. Maxwell

May 01, 2015

News Daily News

La Fibrilación Auricular Post-IAM Acarrea Malos Resultados

Yael L. Maxwell

May 01, 2015

News Daily News

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

April 29, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

News Daily News

很小一部分低风险房颤患者仍然被给予抗凝血剂

Salynn Boyles

April 28, 2015

News Daily News

Una Gran Minoría de Pacientes con Fibrilación Auricular de Bajo Riesgo Siguen Recibiendo Anticoagulantes

Salynn Boyles

April 28, 2015

News Daily News

Substantial Minority of Low-Risk A-fib Patients Still Given Anticoagulants

Salynn Boyles

April 28, 2015

Presentation

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Presenter: K.A. Fiedler

April 22, 2015

News Daily News

Pharmacists May Help Ameliorate Substantial Variation in Dabigatran Adherence

Todd Neale

April 17, 2015

News Industry News

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

March 24, 2015

News Industry News

Boston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device

March 13, 2015

News Daily News

Ultrasound-Assisted Thrombolysis Fails to Boost Thrombus Resolution in Acute Iliofemoral DVT

Todd Neale

January 29, 2015

Advertisement

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

Knowledge Gaps and Misperceptions on Impact of Atrial Fibrillation and Stroke Exist Among Patients, Caregivers and Physicians

Post-TAVR Thrombus May Be More Common Than Thought, Often Subclinical

Silent A-fib After Acute MI Portends Poor Outcome

La Fibrilación Auricular Post-IAM Acarrea Malos Resultados

ISAR-TRIPLE 已发布：6 周与 6 个月三联疗法比较并无净收益

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

很小一部分低风险房颤患者仍然被给予抗凝血剂

Una Gran Minoría de Pacientes con Fibrilación Auricular de Bajo Riesgo Siguen Recibiendo Anticoagulantes

Substantial Minority of Low-Risk A-fib Patients Still Given Anticoagulants

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Pharmacists May Help Ameliorate Substantial Variation in Dabigatran Adherence

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

Boston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device

Ultrasound-Assisted Thrombolysis Fails to Boost Thrombus Resolution in Acute Iliofemoral DVT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content